RNA m6A modification affects tumorigenesis and development of hematological malignancies
10.3760/cma.j.cn114452-20221217-00739
- VernacularTitle:RNA m6A修饰影响血液系统肿瘤发生发展
- Author:
Luyao LONG
1
;
Simei REN
Author Information
1. 北京医院 国家老年医学中心，国家卫生健康委临床检验中心，中国医学科学院老年医学研究院 中国医学科学院北京协和医学院，北京 100730
- Keywords:
Epigenomics;
N6-Methyladenosine;
Hematological malignancies
- From:
Chinese Journal of Laboratory Medicine
2023;46(8):866-871
- CountryChina
- Language:Chinese
-
Abstract:
N6-Methyladenosine (m6A) is one of the most prevalent RNA modifications in mammals. The m6A modification is catalyzed by m6A writers or erasers and involved in various RNA metabolic processes with the recognition by m6A readers. Recently, emerging studies have shown m6A modification is pivotal in fundamental bioprocesses including cell homeostasis and oxidative stress, programmed cell death, cell metabolism, and immune regulation, and accounts for tumoral occurrence and development. To date, abnormal m6A levels and dysregulated related enzymes participate in tumorigenesis and chemoresistance among acute leukemias, chronic myeloid leukemia, multiple myeloma, lymphomas, thus influencing patient prognosis. The mechanisms of m6A modification are sophisticated and varied in different types of malignancies or subtypes. Screening appropriate patients to apply m6A-targeted inhibitors is instructive to the precise treatment of hematological malignancies.
